ABSTRACT
Objetivo: Apresentar a atualização das recomendações do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem, da Sociedade Brasileira de Mastologia e da Federação Brasileira das Associações de Ginecologia e Obstetrícia para o rastreamento do câncer de mama no Brasil. Materiais e Métodos: Foram feitas buscas das evidências científicas publicadas nas bases Medline, EMBASE, Cochrane Library, EBSCO, CINAHL e Lilacs, entre janeiro de 2012 e julho de 2022. As recomendações foram baseadas nessas evidências, mediante consenso da comissão de especialistas das três entidades. Recomendações: O rastreamento mamográfico anual é recomendado para as mulheres de risco habitual entre 40 e 74 anos. Acima de 75 anos, deve ser reservado para as que tenham expectativa de vida maior que sete anos. Mulheres com risco maior que o habitual, entre elas as com mamas densas, com história pessoal de hiperplasia lobular atípica, carcinoma lobular in situ clássico, hiperplasia ductal atípica, tratamento de câncer de mama ou de irradiação no tórax antes dos 30 anos ou, ainda, portadoras de mutação genética ou com forte história familiar, beneficiam-se do rastreamento complementar, sendo consideradas de forma individualizada. A tomossíntese é uma evolução da mamografia e deve ser considerada no rastreamento, sempre que acessível e disponível. (AU)
Objective: To present the update of the recommendations of the Brazilian College of Radiology, the Brazilian Society of Mastology and the Brazilian Federation of Gynecology and Obstetrics Associations for breast cancer screening in Brazil. Materials and Methods: Scientific evidence published in Medline, Embase, Cochrane Library, Ebsco, Cinahl and Lilacs between January 2012 and July 2022 was searched. Recommendations were based on this evidence, by consensus of the expert committee of the three entities. Recommendations: Annual mammographic screening is recommended for women aged between 40 and 74 years old. Above 75 years should be reserved for those with a life expectancy greater than seven years. Women at higher than usual risk, including those with dense breasts, a personal history of atypical lobular hyperplasia, classic lobular carcinoma in situ, atypical ductal hyperplasia, treatment for breast câncer, chest irradiation before age 30, carriers of genetic mutation or with a strong family history, benefit from complementary screening, being considered individually. Tomosynthesis is an evolution of mammography and should be considered in screening, whenever accessible and available. (AU)
Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Breast Neoplasms/prevention & control , Mass Screening/adverse effects , Quality of Life , Thorax/radiation effects , Breast/pathology , Breast Neoplasms/diagnostic imaging , Mammography , Randomized Controlled Trials as Topic , Cohort Studies , Women's Health , Systematic ReviewABSTRACT
Early screening is an important means to reduce breast cancer mortality. In order to solve the problem of low breast cancer screening rates caused by limited medical resources in remote and impoverished areas, this paper designs a breast cancer screening system aided with portable ultrasound Clarius. The system automatically segments the tumor area of the B-ultrasound image on the mobile terminal and uses the ultrasound radio frequency data on the cloud server to automatically classify the benign and malignant tumors. Experimental results in this study show that the accuracy of breast tumor segmentation reaches 98%, and the accuracy of benign and malignant classification reaches 82%, and the system is accurate and reliable. The system is easy to set up and operate, which is convenient for patients in remote and poor areas to carry out early breast cancer screening. It is beneficial to objectively diagnose disease, and it is the first time for the domestic breast cancer auxiliary screening system on the mobile terminal.
Subject(s)
Female , Humans , Breast/pathology , Breast Neoplasms/pathology , Diagnosis, Computer-Assisted , Early Detection of Cancer , Ultrasonography , Ultrasonography, Mammary/methodsSubject(s)
Humans , Female , Adult , Breast/pathology , Cellulite/diagnostic imaging , Breast/diagnostic imaging , Mammography , Tomography, X-Ray ComputedABSTRACT
RESUMEN El carcinoma epidermoide primitivo está considerado el tumor más raro de la mama, con una incidencia que representa solo del 0,04 al 0,075 % de todos los tumores malignos de esta localización. Es una variedad de carcinoma metaplásico constituido por células pavimentosas queratinizantes. Se presenta el caso de un paciente de sexo masculino, de 65 años, de color de piel blanca, residente en el municipio Abreus, provincia Cienfuegos, que acudió a la consulta de mastología de la provincia por presentar una tumoración de 5 cms. en el cuadrante superior externo de la mama derecha, de dos meses de evolución. Se realizó exéresis de la tumoración y se recibió informe de la biopsia con el resultado de carcinoma epidermoide poco diferenciado. Actualmente el paciente se sigue en consulta y está libre de metástasis. Por lo inusual del caso se decide su publicación. Se presenta este reporte por ser el primer paciente de sexo masculino, operado de carcinoma epidermoide de mama en la provincia Cienfuegos.
ABSTRACT Primitive epidermoid carcinoma is considered the rarest breast tumor, with an incidence that represents only 0.04 to 0.05 % of all malignant tumors of this location. It is a variety of metaplastic carcinoma made up of keratinizing pavement cells. The case presented is a 65-year-old white male patient, resident in the Abreus municipality, Cienfuegos province who attended the province's mastology clinic for presenting a 5 cm tumor in the upper external quadrant of the right breast, two months in evolution. Exeresis of the tumor was performed and a report of the biopsy was received with the result of poorly differentiated squamous cell carcinoma. Currently the patient is followed in consultation and is free of metastases. Due to the unusual nature of the case, its publication is decided. This report is presented as the first male patient to undergo surgery for squamous cell carcinoma of the breast in the Cienfuegos province.
Subject(s)
Humans , Male , Aged , Carcinoma, Squamous Cell/pathology , Breast Neoplasms, Male/pathology , Biopsy , Breast/pathology , Carcinoma, Squamous Cell/surgery , Carcinoma, Squamous Cell/diagnosis , Breast Neoplasms, Male/surgery , Breast Neoplasms, Male/diagnosisABSTRACT
Resumen Introducción El tejido mamario ectópico es consecuencia de la involución incompleta de la cresta mamaria. Su localización más frecuente es axilar siendo más común en el sexo femenino. Nuestro objetivo fue presentar el caso de una patología infrecuente en su localización. Materiales y Método Se presenta el caso de una paciente de 39 años, con diagnóstico de cáncer de mama ectópica en la región axilar izquierda. Resultados Presentamos el estudio y la resolución quirúrgica de una paciente con cáncer de mama ectópica. Discusión La presencia de tejido mamario ectópico ocurre en el 2%-6% de la población general. Este tejido sufre cambios fisiopatológicos similares a los de la mama normal, entre los cuales se encuentra la malignización. El carcinoma primario de este tejido es infrecuente y su manifestación más común es el tumor palpable. Conclusiones La incidencia de carcinoma en tejido ectópico es de 0,3% de todos los cánceres de mama. El tratamiento debe seguir las mismas recomendaciones que el cáncer de mama normotópico, con igual estadio TNM.
Introduction Ectopic mammary tissue is consecuence of the incomplete involution of the mammary crest. The most frequent location is the axillary region and more common in women. Our gol was present the case of an infrequent pathology in its location. Materials and Method A case of a 39-year-old patient with a diagnosis of ectopic breast cancer in the left axillary region. Results We present the study and surgical resolution of a patient with ectopic breast cancer. Discussion Ectopic breast tissue occurs in 2-6% of the general population. This tissue undergoes pathophysiological changes similar to those of the normal breast, among which malignancy is found. The primary carcinoma of this tissue is infrequent and its most common manifestation is the palpable tumor. Conclussion The incidence of carcinoma in ectopic tissue is approximately 0.3% of all breast cancers. Treatment should follow the same recommendations as those for breast tumors with the same TNM stage.
Subject(s)
Humans , Female , Adult , Axilla/surgery , Axilla/pathology , Breast/pathology , Breast Neoplasms/diagnostic imaging , Mastectomy/methods , Neoplasms, Unknown Primary , Breast Neoplasms/surgery , Breast Neoplasms/complications , MammographyABSTRACT
Se presentó el caso de una adolescente de 12 años de edad que acudió a consulta externa de Cirugía del Hospital Pediátrico Docente "Gral. Pedro Agustín Pérez", de Guantánamo; la misma presentó aumento de volumen a nivel del cuadrante superior externo de la mama izquierda, no doloroso. Se palpó tumoración de bordes irregulares, o sea mal definidos, de 3 cm de diámetro aproximadamente, sin signos de inflamación. Se realizó biopsia por aspiración con aguja fina y se informó el diagnóstico de fibroadenoma de mama. La exéresis del nódulo y el estudio histopatológico demostraron el diagnóstico de linfoma no Hodgkin de alto grado de malignidad y se procedió a la atención multidisciplinaria. Al momento del reporte la paciente continúa con quimioterapia y evoluciona satisfactoriamente. Se revisó la literatura médica sobre el tema y se expusieron sus bases esenciales para la familiarización de los médicos generales(AU)
A 12 years old young female presented to the surgical outpatient clinic at the Hospital Pediátrico Docente "Gral. Pedro Agustín Pérez" in Guantanamo. Patient showed swelling in the upper right breast, with no pain. Examination revealed irregular edges (with approximately 3 cm in diameter) and no swollen tissue. Fine-needle aspiration biopsy was performed and breast fibroadenoma was diagnosed. Node exeresis and histopathological study both showed a high risk malignant non-Hodgkin's lymphoma, and a multidisciplinary care team assumed the case. At the time of the report, the patient is still under chemotherapy and prognosis evolves positively. The medical literature on the subject was put on review and a layout of the essentials to familiarize the general practitioners with the topic was set(AU)
Subject(s)
Humans , Adolescent , Lymphoma, Non-Hodgkin/diagnosis , Breast/pathology , Breast Neoplasms , Fibroadenoma/pathologyABSTRACT
Abstract Objective To investigate the action of testosterone (T), isolated or associated with estradiol benzoate (EB), on the proliferation markers and apoptosis of breasts of ovariectomized rats. Methods A total of 48 castrated female Wistar rats were divided into 6 groups, and each of them were submitted to one of the following treatments for 5 weeks: 1) control; 2) EB 50 mcg/day + T 50 mcg/day; 3) T 50mcg/day; 4) EB 50 mcg +T 300 mcg/day; 5) T 300 mcg/day; and 6) EB 50 mcg/day. After the treatment, the mammary tissue was submitted to a histological analysis and immunoexpression evaluation of proliferation markers (proliferating cell nuclear antigen, PCNA) and apoptosis (caspase-3). Results There was a statistically significant difference among the groups regarding microcalcifications and secretory activity, with higher prevalence in the groups treated with EB. There was no difference among the groups regarding atrophy, but a higher prevalence of atrophy was found in the groups that received T versus those that received EB +T. There was a difference among the groups regarding the PCNA (p = 0.028), with higher expression in the group submitted to EB +T 300 mcg/day. Regarding caspase-3, there was no difference among the groups; however, in the group submitted to EB +T 300 mcg/day, the expression was higher than in the isolated T group. Conclusion Isolated T did not have a proliferative effect on the mammary tissue, contrary to EB. Testosterone in combination with EB may or may not decrease the proliferation, depending on the dose of T.
Resumo Objetivo Investigar a ação da testosterona (T) isolada ou associada ao benzoato de estradiol (EB) na proliferação e apoptose de mamas de ratas ovariectomizadas. Métodos Um total de 48 ratas Wistar castradas foram divididas em 6 grupos, e cada um foi submetido a um dos seguintes tratamentos durante 5 semanas: 1) controle; 2) BE 50 mcg/dia + T 50mcg/dia; 3) T 50 mcg/dia; 4) BE 50 mcg + T 300mcg/dia; e) T 300 mcg/dia; e f) BE 50 mcg/dia. Após o tratamento, o tecido mamário foi submetido a análise histológica e avaliação de imunoexpressão de marcadores de proliferação (antígeno nuclear de células proliferantes, PCNA) e apoptose (caspase-3). Resultados Houve diferença estatisticamente significante entre os grupos com relação às microcalcificações e à atividade secretora, com maior prevalência nos grupos tratados com BE. Não houve diferença entre os grupos quanto à atrofia, mas houve maior prevalência de atrofia nos grupos que receberam T versus os que receberam BE+ T. Houve diferença entre os grupos quanto ao ANCP (p= 0,028), com maior expressão no grupo BE+ T 300 mcg/dia. Com relação à caspase-3, não houve diferença entre os grupos, mas, no grupo BE+ T 300 mcg/dia, a expressão foi maior do que no grupo de T isolada. Conclusão A T isolada não apresentou efeito proliferativo do tecido mamário, contrariamente ao EB. A T em associação ao EB pode diminuir ou não a proliferação, a depender da dose de T.
Subject(s)
Animals , Female , Testosterone/pharmacology , Breast/cytology , Apoptosis/drug effects , Cell Proliferation/drug effects , Breast/pathology , Calcinosis/pathology , Ovariectomy , Biomarkers/analysis , Rats, Wistar , Proliferating Cell Nuclear Antigen/analysis , Estradiol/analogs & derivatives , Estradiol/pharmacology , Caspase 3/analysisABSTRACT
Abstract: Objective: To describe the rationale and the methodology of a multicenter project to study the etiology of breast cancer in young Latin American women. Materials and methods: The International Agency for Research on Cancer has established an international collaborative population-based case-control study in four countries in Latin America: Chile, Colombia, Costa Rica, and Mexico (the PRECAMA study). Standardized methodologies were developed to collect information on reproductive variables, lifestyle, anthropometry, diet, clinical and pathological data, and biological specimens. The study will be extended to other countries in the region. Conclusion: PRECAMA is unique in its multidisciplinary approach that combines genetics, genomics, and metabolomics with lifestyle factors. The data generated through this project will be instrumental to identify major risk factors for molecular subtypes of breast cancer in young women, which will be important for prevention and targeted screening programs in Latin America.
Resumen: Objetivo: Describir la justificación y la metodología para el establecimiento de un proyecto multicéntrico sobre el cáncer de mama en mujeres jóvenes de América Latina. Material y métodos: La Agencia Internacional para la Investigación del Cáncer (IARC) ha establecido un estudio colaborativo internacional de casos y controles con base poblacional en cuatro países de América Latina: Chile, Colombia, Costa Rica y México (el estudio PRECAMA). Se han desarrollado metodologías estandarizadas para recolectar información sobre variables reproductivas, estilos de vida, antropometría y dieta, datos clínicos y patológicos y muestras biológicas. Conclusión: PRECAMA es único en su enfoque multidisciplinario. Los datos generados a través de este proyecto serán fundamentales para identificar los principales factores de riesgo del cáncer de mama en mujeres jóvenes. Los hallazgos serán relevantes para la prevención y los programas de detección oportuna en América Latina, con beneficios clínicos inmediatos.
Subject(s)
Humans , Female , Adult , Young Adult , Breast Neoplasms/etiology , Specimen Handling/methods , Breast/pathology , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Exercise , Case-Control Studies , Chile , Risk Factors , Colombia , Patient Selection , Costa Rica , Eating , Informed Consent , Latin America , Life Style , MexicoABSTRACT
RESUMEN El cáncer de mama en el sexo masculino es una entidad clínica poco frecuente, tiene una presentación unimodal a los 71 años de edad, generalmente se presenta de manera similar a la forma en que se presenta en el sexo femenino. Su causa es poco conocida. Los sarcomas son tumores de componentes mesenquimatoso que constituyen del 0,2-1 % de todos los tumores de mama, y menos del 5 % del total. El sarcoma neurogénico, a su vez, es un tumor extremadamente raro. Representa del 1-2 % aproximadamente, de los tumores de los nervios periféricos con transformación maligna. Debido a la rareza geográfica e histopatológica de este tipo y mucho más en pacientes masculinos se presentó este caso. Paciente masculino de 57 años de edad, con el diagnóstico de un sarcoma de la mama derecha. Se le realizó una mastectomía radical más quimioterapia y radioterapia adyuvante. Los estudios de inmunohistoquímicos permitieron llegar al diagnóstico de sarcoma neurogénico.
ABSTRACT Breast cancer in men (BCM) is a rare clinical entity that has a unimodal presentation at the age of 71 years, and generally presents in a similar way it presents in the female sex. Its etiology remains almost unknown. Sarcomas are tumors of mesenchymal components representing from 0.2 to 1 % of all the breast tumors and less than 5 % of the total. The neurogenic sarcoma is also an extremely rare tumor. It represents around 1-2 % of the peripheral nerves tumors with malignant transformations. Due to location and histopathological rarity of this kind of tumors, much more in male patients, the authors presented the case of a male patient, aged 57 years, with the diagnosis of a left breast sarcoma. He undergone a radical mastectomy plus adjuvant chemotherapy and radiotherapy. The immunohystochemical studies allowed arriving to the diagnosis of neurogenic sarcoma.
Subject(s)
Humans , Male , Middle Aged , Breast/pathology , Immunohistochemistry/methods , Breast Neoplasms, Male/surgery , Breast Neoplasms, Male/diagnosis , Breast Neoplasms, Male/etiology , Breast Neoplasms, Male/pathology , Breast Neoplasms, Male/drug therapy , Breast Neoplasms, Male/radiotherapy , Mastectomy , Sarcoma, Clear Cell , Neurofibrosarcoma/surgery , Neurofibrosarcoma/diagnosis , Neurofibrosarcoma/etiology , Neurofibrosarcoma/pathologySubject(s)
Humans , Female , Physical Examination , Axilla/pathology , Breast/pathology , Early DiagnosisABSTRACT
El cáncer de Mama es el tumor más frecuente de la mujer y su incidencia va en aumento. En la atención primaria del paciente, se debe establecer el riesgo de padecer cáncer de mama durante la vida, a través de una historia clínica orientada a los factores de riesgo familiares e individuales, de tal forma que podamos implementar las estrategias de tamizaje apropiadas. Las estrategias de tamizaje deben ser aplicadas de manera sistemáticas, y los resultados anormales referidos a un centro con experiencia en el diagnóstico. Los pacientes diagnosticados deben ser evaluador por un equipo multidisciplinario con experiencia en el manejo de la muestra, estadificación y tratamiento del cáncer de mama.
Breast cancer is the most frequent tumor in women and its incidence is increasing. In the primary care of the patient, the risk of suffering from breast cancer should be established during life, through a clinical history focused on family and individual risk factors, in such a way that we can implement the appropriate screening strategies. Screening strategies should be applied systematically, and abnormal results referred to a center with experience in diagnosis . Patients diagnosed should be evaluated by a multidisciplinary team with experience in the management of the sample, staging and treatment of breast cancer.
Subject(s)
Humans , Female , Middle Aged , Breast Neoplasms/blood , Mass Screening , Biopsy, Large-Core Needle/methods , Breast/pathology , Breast Neoplasms/diagnosis , Neoplasm StagingABSTRACT
SUMMARY OBJECTIVE: To assess the cosmetic satisfaction of patients diagnosed with breast cancer submitted to the hypofractionated radiotherapy with IMRT (hIMRT) technique and its correlation with dosimetric data of the radiotherapy planning. MATERIALS AND METHODS: The retrospective cohort study that assessed women with a diagnosis of malignant breast neoplasia submitted to the conservative treatment or radical mastectomy and treated with hIMRT. In the period between August 2007 to December 2014, in a philanthropic / private institution, 170 records were selected. The cosmetic assessment was carried out by means of the Harvard/RTOG/NSABP scale with one-year minimum range after treatment. The collected dosimetric data were: breast / chest wall volume, volume that received 95% (V95%) and 107% (V107%) of the prescribed dose. RESULTS: The volume of the treated breasts ranged from 169 to 2.103 ml (median = 702; IQR: 535 to 914 ml). Median V95% was 86.7% (54.6-96.6%; IQR: 80.0% to 90.6%); eight (5.7%) patients had V95% higher than 95%. Median V107% was 0% (0%-16.3%; IQR: 0.0% to 0.3% and 13); 9.3% patients had V107% higher than 2%. One hundred and thirty-three (78.2%) patients responded to the cosmetic assessment: 99 (74.4%) considered the cosmetic results excellent. Significant associations between cosmetic assessment and breast volume (p=0.875), V95% (p=0.294) e V107% (p=0.301) were not found. CONCLUSION: The cosmetic results showed favorable when using hIMRT, and the lack of correlation with usual the dosimetric data illustrates the capacity of hIMRT to minimize the heterogeneity of the dose in this endpoint, even in voluminous breasts.
RESUMO OBJETIVO: Avaliar a satisfação cosmética de pacientes diagnosticadas com câncer de mama submetidas à radioterapia hipofracionada com técnica IMRT (hIMRT) e sua correlação com dados dosimétricos do planejamento radioterápico. MATERIAIS E MÉTODOS: Estudo de coorte retrospectivo que avaliou mulheres com diagnóstico de neoplasia maligna de mama submetidas a tratamento conservador ou mastectomia radical e tratadas com hIMRT. No período de agosto de 2007 a dezembro de 2014, em uma instituição filantrópica/particular, foram selecionados 170 prontuários. A avaliação cosmética foi feita por meio da escala de Harvard/RTOG/NSABP com um intervalo mínimo de um ano após o tratamento. Dados dosimétricos coletados foram: volume da mama/plastrão, volume que recebeu 95% (V95%) e 107% (V107%) da dose prescrita. RESULTADOS: O volume das mamas tratadas variou de 169 a 2.103 ml (mediana = 702; IQR: 535 a 914 ml). O V95% mediano foi 86,7% (54,6-96,6%; IQR: 80,0% a 90,6%); oito (5,7%) pacientes tiveram o V95% superior a 95%. O V107% mediano foi 0% (0%-16,3%; IQR: 0,0% a 0,3% e 13); 9,3% pacientes tiveram o V107% superior a 2%. Cento e trinta e três (78,2%) pacientes responderam à avaliação cosmética: 99 (74,4%) consideraram o resultado cosmético excelente. Não foram encontradas associações significativas entre a avaliação cosmética e o volume da mama (p=0,875), V95% (p=0,294) e V107% (p=0,301). CONCLUSÕES: Os resultados cosméticos mostraram-se favoráveis com o uso de hIMRT, e a ausência de correlação com os dados dosimétricos usuais ilustra a capacidade do hIMRT em minimizar a heterogeneidade da dose neste desfecho, mesmo em mamas volumosas.
Subject(s)
Humans , Female , Adult , Aged , Aged, 80 and over , Body Image , Breast Neoplasms/radiotherapy , Radiotherapy, Intensity-Modulated/methods , Radiation Dose Hypofractionation , Breast/pathology , Breast Neoplasms/surgery , Breast Neoplasms/pathology , Retrospective Studies , Radiotherapy, Conformal/methods , Radiotherapy, Conformal/statistics & numerical data , Radiotherapy, Intensity-Modulated/statistics & numerical data , Mastectomy , Middle AgedABSTRACT
Las lesiones mamarias se dividen histológicamente en dos grandes grupos, malignas y benignas. Las lesiones malignas pueden ser de origen ductal o lobulillar, siendo el carcinoma ductal infiltrante la neoplasia invasiva más frecuente. Las lesiones benignas se clasifican en no proliferativas, proliferativas sin atipias y proliferativas con atipias. Dentro de los dos últimos grupos se encuentran entidades que conllevan un alto riesgo de desarrollar carcinoma de mama, como pueden ser la hiperplasia ductal atípica, la cicatriz radial o la neoplasia lobular. Revisamos en qué consisten dichas entidades y cuáles son sus características principales en imagen, fundamentalmente en mamografía y ecografía. Si tras realizar una biopsia se obtiene uno de esos diagnósticos histológicos, es importante analizar las características imagenológicas y el tipo de procedimiento realizado (número de cilindros obtenidos, calibre de aguja...), para realizar un adecuado manejo posterior. En algunos casos la actitud a seguir será la extirpación quirúrgica completa de la lesión, mientras que en otros se podrá realizar una extirpación percutánea (mediante biopsia con aguja de vacio), o incluso seguimiento estricto por imagen. Mediante diferentes casos mostraremos nuestra experiencia y analizaremos la literatura vigente para recordar esas entidades y llegar a un consenso adecuado sobre el manejo de las mismas.
Breast lesions are divided histologically into two large groups, malignant and benign. Malignant lesions may be of ductal or lobular origin, with infiltrating ductal carcinoma being the most frequent invasive neoplasm. Benign breast lesions are classified as proliferative, proliferative without atypia and proliferative with atypia. Within the last two classifications are entities that carry a high risk of developing breast carcinoma, such as atypical ductal hyperplasia, radial scar or lobular neoplasia. We review what these entities consist of and what are their fundamental characteristics in image, fundamentally in mammography and ultrasound. When we perform one of these histological diagnoses after a biopsy, it is important to analyze the radiological characteristics and the type of procedure performed (number of cylinders, needle gauge ...) to perform an appropriate posterior management. In some cases the attitude to be followed will be the complete surgical removal of the lesion, while in others a percutaneous excision (through vacuum needle biopsy) or even strict image follow-up may be performed. Through different cases we will show our experience and analyze current literature to remember these entities and reach an adequate management consensus.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Breast/injuries , Breast/pathology , Breast/diagnostic imaging , Breast Neoplasms/diagnostic imaging , Carcinoma, Intraductal, Noninfiltrating/diagnostic imaging , Phyllodes Tumor/diagnostic imaging , Fasciitis/diagnostic imaging , Breast Carcinoma In Situ/diagnostic imaging , Tamoxifen/therapeutic use , Breast/surgery , Mammography , Magnetic Resonance Spectroscopy , Ultrasonography , Carcinoma, Intraductal, Noninfiltrating/surgery , Carcinoma, Intraductal, Noninfiltrating/drug therapy , Phyllodes Tumor/surgery , Raloxifene Hydrochloride/therapeutic use , Aromatase Inhibitors/therapeutic use , Fasciitis/surgery , Breast Carcinoma In Situ/surgery , Breast Carcinoma In Situ/drug therapySubject(s)
Humans , Breast/pathology , Mammography , Cardiovascular Diseases/diagnosis , Vascular CalcificationABSTRACT
Abstract: Angiosarcoma is a rare and aggressive tumor with high rates of metastasis and relapse. It shows a particular predilection for the skin and superficial soft tissues. We report three distinct and typical cases of angiosarcoma that were diagnosed in a single dermatology clinic over the course of less than a year: i) Angiosarcoma in lower limb affected by chronic lymphedema, featuring Stewart-Treves syndrome; ii) a case of the most common type of angiosarcoma loated in the scalp and face of elderly man and; iii) a skin Angiosarcoma in previously irradiated breast. All lesions presented characteristic histopathological findings: irregular vascular proliferation that dissects the collagen bundles with atypical endothelial nuclei projection toward the lumen.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged, 80 and over , Scalp/pathology , Skin Neoplasms/pathology , Head and Neck Neoplasms/pathology , Hemangiosarcoma/pathology , Breast/pathology , Risk Factors , Leg/pathology , Lymphangiosarcoma , Lymphedema/complicationsABSTRACT
La gigantomastia juvenil es una afección médica benigna poco frecuente que causa el crecimiento excesivo y discapacitante de las mamas, provocando importantes trastornos físicos y psíquicos a pacientes púberes o adolescentes. Presentamos el caso en una paciente de 23 años, la cual se encontraba en la última etapa de su patología con una importante signosintomatología. Al no existir un tratamiento específico para ella, la mastoplastia reductiva es el procedimiento más efectivo con el que se cuenta. Se realizó una reducción de 9000 g de tejido mamario mediante la técnica de Torek, obteniendo mamas de volumen medio, simétricas, con cicatrices aceptables. La complejidad de esta patología hace que debamos manejarnos con un equipo multidisciplinario, tanto durante su estudio como en su tratamiento, y consideramos muy importante realizar un seguimiento estricto a largo plazo ya que es posible que, después del tratamiento quirúrgico, se presenten recurrencias.
Juvenile gigantomastia is a rare benign medical condition that causes excessive and disabling growth of the breasts and provokes considerable physical and psychological discomfort in patients in their puberty and adolescence. We introduce the case of a 23-year-old patient in the last stage of her condition with considerable signs and symptoms. There is no specific treatment for juvenile gigatomastia; hence breast reduction is the most effective procedure available. A reduction of 9,000 grams of breast tissue was performed using Torek's technique, resulting in medium volume, symmetrical breasts with acceptable scars. The complexity of this disorder requires a multidisciplinary team during the study and therapy stages. A strict long-term follow-up is recommended as relapses are possible after surgery.
Subject(s)
Humans , Adult , Breast/pathology , Mastectomy, Subcutaneous , Mammaplasty/methods , Hypertrophy/pathologyABSTRACT
Abstract. Breast calcifications are frequent findings in mammography. Most of them have a benign origin, such as in the case of the response to inflammatory disease of the ducts or coarse calcifications in benign nodules. Many of these calcifications show a characteristic benign appearance, and they do not need to be magnified or monitored. However, other calcifications can show a grouped pattern, have a suspicious appearance, and transform into an in situ ductal carcinoma or a high risk breast lesion. It is important to know the morphological and distribution patterns of these calcifications in order to make right decisions for each case. In the 5th edition of the BI-RADS atlas, 2013, categories and levels of suspicion for some patterns were modified. The objective of this article is to update descriptors and categories of BI-RADS micro-calcifications, pointing out their most important features and malignancy risk linked to each descriptor.
Resumen. Las calcificaciones mamarias son un hallazgo frecuente en mamografía. La mayoría de ellas tienen un origen benigno, como puede ser la respuesta a patología inflamatoria de los conductos o calcificaciones gruesas en nódulos benignos. Muchas de estas calcificaciones presentan un aspecto benigno característico y no requieren ser magnificadas o controladas. Otras calcificaciones sin embargo pueden presentarse agrupadas, tener un aspecto sospechoso y originarse en un carcinoma ductal in situ o una lesión de alto riesgo. Es relevante conocer los patrones morfológicos y de distribución de estas calcificaciones a fin de tomar la conducta adecuada para cada caso. En la 5.ª edición del atlas BI-RADS, 2013, las categorías y grados de sospecha de algunos patrones fueron modificados. El objetivo del presente artículo es realizar una actualización de los descriptores y las categorías BI-RADS de las microcalcificaciones, señalando sus características más importantes y el riesgo de malignidad asociado a cada descriptor.